J&J Split To Have Limited China Business Impact?
With Conglomerate Model Outdated, US Health Care Giant Pivots To Agility
Executive Summary
China is a major emerging market for J&J’s pharma, medical and consumer health businesses and the planned spinout of the consumer business is likely to allow the US giant to focus on key new drugs in a fast-changing and competitive market while retaining medtech growth. But the consumer sector will continue to face challenges and might learn from similar moves by other multinationals in China.